Compare CMU & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMU | TIL |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.5M | 177.1M |
| IPO Year | N/A | 2021 |
| Metric | CMU | TIL |
|---|---|---|
| Price | $3.48 | $10.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $100.67 |
| AVG Volume (30 Days) | ★ 82.4K | 72.7K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $47.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.78 | $10.70 |
| 52 Week High | $3.38 | $42.79 |
| Indicator | CMU | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 46.72 | 36.08 |
| Support Level | $3.46 | $10.76 |
| Resistance Level | $3.53 | $11.51 |
| Average True Range (ATR) | 0.02 | 0.73 |
| MACD | -0.00 | 0.16 |
| Stochastic Oscillator | 28.57 | 2.71 |
Mfs High Yield Municipal Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company invest various top Healthcare companies, Airport, Universities (Secondary Schools), Universities (Dormitories), and many more, out of maximum revenue is gained from Healthcare Hospitals and Long Term Care.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.